<HTML>
<HEAD>
<TITLE>Filed by Bowne Pure Compliance</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV style="font-size: 10pt">
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>


<P align="center" style="font-size: 14pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P align="center" style="font-size: 18pt"><B>FORM 8-K</B>

<P align="center" style="font-size: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P align="center" style="font-size: 10pt"><B>Date of Report (Date of earliest event reported): February 6, 2009</B>

<P align="center">

<P align="center" style="font-size: 24pt"><B>HEARTWARE INTERNATIONAL, INC.<BR></B>
<FONT style="font-size: 10pt">(Exact name of registrant as specified in its charter)
</FONT>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="32%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="33%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="32%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>Delaware</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>000-52595</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>26-3636023</B></TD>
</TR>
<TR valign="top">
    <TD>(State or other Jurisdiction of Incorporation)</TD>
    <TD>&nbsp;</TD>
    <TD>(Commission File Number)</TD>
    <TD>&nbsp;</TD>
    <TD>(IRS Employer Identification No.)</TD>
</TR>
</TABLE>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>205 Newbury Street, Suite 101<BR>Framingham, MA<BR></B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>01701</B></TD>
</TR>
<TR valign="top">
    <TD>(Address of Principal Executive Offices)</TD>
    <TD>&nbsp;</TD>
    <TD>(Zip Code)</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt">Registrant&#146;s telephone number, including area code: <B>508.739.0950</B>


<TABLE border="0" width="30%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="100%">&nbsp;</TD>
</TR>
<TR>
    <TD nowrap style="border-bottom: 1px solid #000000"><B>&nbsp;</B></TD>
</TR>
<TR>
    <TD nowrap>(Former name or former address if changed since last report.)</TD>
</TR>
</TABLE>

<P align="left" style="font-size: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:

<P align="left" style="font-size: 10pt">
<FONT face="Wingdings">&#111;</FONT> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<P>
<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>

</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P align="left" style="font-size: 10pt"><B>Item&nbsp;7.01 Regulation&nbsp;FD Disclosure</B>


<P align="left" style="font-size: 10pt">HeartWare International, Inc. (ASX:HIN) announced that it has appointed Keith Aaronson, M.D. to be the Co-Principal
Investigator for its Bridge-to-Transplant trial in the United States. Dr.&nbsp;Aaronson joins Dr.&nbsp;Mark Slaughter, whose
appointment as Principal Investigator was announced in December&nbsp;2008.


<P align="left" style="font-size: 10pt">Dr.&nbsp;Aaronson is Medical Director of the Heart Transplant Program and Co-Director of the Heart Failure and Transplant
Management Program at the University of&nbsp;Michigan&nbsp;Medical Center. He is Associate Professor of Medicine in the Division
of Cardiovascular Medicine at the University of&nbsp;Michigan. &nbsp;A renowned heart failure cardiologist, Dr.&nbsp;Aaronson is a
member of the editorial board of the American College of Cardiology Cardiosource Review Journal and a reviewer for the
leading American and European journals of medicine and cardiology and for the annual sessions of the&nbsp;American College
of Cardiology, the American Heart Association, the International Society for Heart and Lung Transplantation and the
Heart Failure Society of America. &nbsp;Dr.&nbsp;Aaronson has authored over 50 peer reviewed publications and 9 book chapters.&nbsp;
He has held leadership positions in a number of clinical trials, has authored over 100 abstracts and has presented
widely at national and international conferences.


<P align="left" style="font-size: 10pt">A copy of the complete ASX announcement is attached.


<P align="left" style="font-size: 10pt"><B>Item&nbsp;9.01 Financial Statements and Exhibits</B>


<P align="left" style="font-size: 10pt">Exhibit&nbsp;99.1 HeartWare International, Inc. ASX announcement, dated February&nbsp;6, 2009


<P align="left" style="font-size: 10pt"><B>SIGNATURES</B>


<P align="left" style="font-size: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly authorized.

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="36%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="51%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">HeartWare International, Inc.<BR>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Date: February&nbsp;6, 2009
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>/</B>s/ David McIntyre</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD nowrap colspan="2" align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: David McIntyre</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Chief Financial Officer and
Chief Operating Officer</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">2




</DIV>
</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "c80585e8vk.htm", "description": "FORM 8-K", "secsgml_size_bytes": 8227}]
{"company-data": {"conformed-name": "HeartWare International, Inc.", "cik": "0001389072", "assigned-sic": "3841", "irs-number": "980498958", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-52595", "film-number": "09574772"}, "business-address": {"street1": "14000 NW 57TH COURT", "city": "MIAMI LAKES", "state": "FL", "zip": "33014", "phone": "508-739-0841"}, "mail-address": {"street1": "205 NEWBURY STREET", "street2": "SUITE 101", "city": "FRAMINGHAM", "state": "MA", "zip": "01701"}, "former-company": {"former-conformed-name": "HeartWare LTD", "date-changed": "20070206"}}
Filed by Bowne Pure Compliance
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 6, 2009
HEARTWARE INTERNATIONAL, INC.
(Exact name of registrant as specified in its charter)
Delaware
000-52595
26-3636023
(State or other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
205 Newbury Street, Suite 101
Framingham, MA
01701
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number, including area code:
508.739.0950
(Former name or former address if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure
HeartWare International, Inc. (ASX:HIN) announced that it has appointed Keith Aaronson, M.D. to be the Co-Principal
Investigator for its Bridge-to-Transplant trial in the United States. Dr. Aaronson joins Dr. Mark Slaughter, whose
appointment as Principal Investigator was announced in December 2008.
Dr. Aaronson is Medical Director of the Heart Transplant Program and Co-Director of the Heart Failure and Transplant
Management Program at the University of Michigan Medical Center. He is Associate Professor of Medicine in the Division
of Cardiovascular Medicine at the University of Michigan.  A renowned heart failure cardiologist, Dr. Aaronson is a
member of the editorial board of the American College of Cardiology Cardiosource Review Journal and a reviewer for the
leading American and European journals of medicine and cardiology and for the annual sessions of the American College
of Cardiology, the American Heart Association, the International Society for Heart and Lung Transplantation and the
Heart Failure Society of America.  Dr. Aaronson has authored over 50 peer reviewed publications and 9 book chapters. 
He has held leadership positions in a number of clinical trials, has authored over 100 abstracts and has presented
widely at national and international conferences.
A copy of the complete ASX announcement is attached.
Item 9.01 Financial Statements and Exhibits
Exhibit 99.1 HeartWare International, Inc. ASX announcement, dated February 6, 2009
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly authorized.
HeartWare International, Inc.
Date: February 6, 2009
By:
/
s/ David McIntyre
Name: David McIntyre
Title: Chief Financial Officer and
Chief Operating Officer